Add BrightSurf on Google Email

New drug candidate reverses obesity in mice

Researchers at Karolinska Institutet have discovered a new class of drugs that block mitochondrial function and reverse diet-induced obesity, fatty liver, and diabetes in mice. The treatment increased fat metabolism, leading to drastic weight loss and restored glucose tolerance.

SourceKarolinska Institutet·JournalNature Metabolism·TypeExperimental study·DateApr 30, 2024

New evidence-based guideline for the management of osteoporosis in men

The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis have issued new guidelines for managing osteoporosis in men. These recommendations cover disease burden, fracture risk assessment, treatment thresholds, and interventions to reduce the substantial morbidity and mortality ass...

SourceInternational Osteoporosis Foundation·JournalNature Reviews Rheumatology·TypeLiterature review·DateMar 25, 2024

An avocado a day may improve overall diet quality, researchers report

A team led by Kristina Petersen and Penny Kris-Etherton found that eating avocados daily significantly increased participants' adherence to dietary guidelines. The study suggested that using avocados as a substitute for refined grains and sodium may play a role in achieving improved diet quality.

SourcePenn State·JournalCurrent Developments in Nutrition·TypeRandomized controlled/clinical trial·DateMar 22, 2024

Overeating and starving both damage the liver: Cavefish provide new insight into fatty liver disease

Researchers have identified a gene responsible for the development of starvation-induced fatty liver in cavefish, which are able to protect their liver due to reduced fat accumulation. This genetic basis has implications for understanding and addressing liver conditions in humans, including Type 2 diabetes and obesity.

SourceStowers Institute for Medical Research·JournalLife Science Alliance·TypeExperimental study·DateMar 18, 2024

Women with high-risk HPV and metabolic syndrome have almost three times risk for mortality, York University researchers find

Researchers at York University found that women with both high-risk human papillomavirus (HPV) and metabolic syndrome are at a significantly higher risk of mortality. The study analyzed data from over 5,000 individuals and found that those with both conditions had a 2.6 times higher risk for mortality than those without either condition.

SourceYork University·JournalPLOS ONE·TypeData/statistical analysis·DateMar 8, 2024

Potential new target and drug candidate for Barth syndrome

Researchers at the University of Pittsburgh have discovered a potential new target for treating Barth syndrome, a rare genetic disease with devastating consequences. They identified a molecular culprit that could be targeted to potentially reverse the disease course and developed a small-molecule drug candidate to correct genetic tafaz...

SourceUniversity of Pittsburgh·JournalNature Metabolism·TypeExperimental study·DateNov 23, 2023

Study reveals gaps in fracture risk communication and patients’ preferences for visual representation

A new study has found that most patients with osteoporosis want to receive information on their fracture risk, but only half of them actually get it. Patients prefer visual representations, such as graphs with a colored traffic-light system, to communicate fracture risk and are more likely to take medication if presented in this way.

SourceInternational Osteoporosis Foundation·JournalOsteoporosis International·TypeExperimental study·DateNov 20, 2023

Type 2 diabetes and colorectal cancer risk

A study of 54,000 participants found that diabetes was associated with an elevated risk of colorectal cancer. The association was attenuated for those who completed colonoscopies, highlighting the potential benefits of preventative screening.

SourceJAMA Network·JournalJAMA Network Open·DateNov 14, 2023

International clinical trial finds that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity who don’t have diabetes

A recent clinical trial found that semaglutide significantly reduced cardiovascular events in adults with overweight or obesity who do not have diabetes. The medication was shown to lower the risk of death from cardiovascular causes, nonfatal heart attacks, and strokes by 20% compared to placebo.

SourceCleveland Clinic·JournalNew England Journal of Medicine·DateNov 11, 2023

New study sheds light on the molecular mechanisms underlying lipid recycling within cells

A recent study published in the Journal of Cell Biology has made significant progress in understanding autophagy and lipid recycling. Researchers used yeast as a model organism to identify key players in the process, including Atg15, Pep4, and Prb1, and demonstrated that Pep4 and Prb1 activate Atg15 to break down phospholipid bilayers.

SourceTokyo Institute of Technology·JournalJournal of Cell Biology·TypeExperimental study·DateNov 2, 2023

Exercise-mimicking drug sheds weight, boosts muscle activity in mice

A new exercise-mimicking drug, SLU-PP-332, has shown promising results in obese mice, leading to weight loss and increased muscle activity without increasing physical activity. The drug works by boosting a natural metabolic pathway, making the body act like it is training for a marathon, resulting in faster metabolism of fat.

SourceUniversity of Florida·JournalJournal of Pharmacology and Experimental Therapeutics·TypeExperimental study·DateSep 25, 2023

Fiber from crustaceans, insects, mushrooms promotes digestion

A new study found that digesting fiber from crustaceans, insects, and mushrooms in mice engages the immune system, leading to less weight gain, reduced body fat, and a resistance to obesity. The researchers discovered that an active immune response was triggered by chitin digestion, which is insoluble and requires enzymes to break down.

SourceWashU Medicine·JournalScience·TypeExperimental study·DateSep 7, 2023

Collaboration and targeted activities drive post-fracture care improvement: insights from the Capture the Fracture® Partnership

The Capture the Fracture Partnership has successfully driven global Fracture Liaison Services implementation, effectiveness, and sustainability. The partnership's unique approach, including policy, coalitions, mentorship, and scalable solutions, has delivered impactful resources and activities to prioritize secondary fracture prevention.

SourceInternational Osteoporosis Foundation·JournalOsteoporosis International·TypeSurvey·DateJul 24, 2023

AMP biosynthesis key to longevity and metabolic health in vertebrates

A recent study led by Dr. Itamar Harel reveals that manipulating AMP biosynthesis can extend lifespan and promote metabolic health in vertebrates. The research used the turquoise killifish as a model organism and found remarkable effects on energy metabolism, including a fasting-like profile and enhanced resistance to high-fat diets.

SourceThe Hebrew University of Jerusalem·JournalDevelopmental Cell·TypeExperimental study·DateJul 12, 2023

Metformin's role in preventing metabolic syndrome during androgen deprivation therapy: a Phase II study

A randomized phase II study found that adding metformin to androgen deprivation therapy did not reduce the risk of metabolic syndrome or improve PSA response in patients with advanced prostate cancer. Metformin showed some antitumor effects through mTOR inhibition, but these were not significant.

SourceImpact Journals LLC·JournalOncotarget·TypeRandomized controlled/clinical trial·DateJun 20, 2023

The Endocrine community joins forces on European Hormone Day to raise awareness of vital role of hormones in preventing and treating rare and chronic diseases

The European Society of Endocrinology, ESE Foundation, and other partners mark the second European Hormone Day to promote better understanding of hormone roles and encourage change in health policy. The 'Milano Declaration' calls for stronger inclusion of endocrine health perspective in European policies.